Company: CWAN
Filing Date: 2025-01-13
Form Type: 425
Source: 0001193125-25-004988
Chunk: 7

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-01-13
Form: 425
Chunk 7
---

the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of management of the Company and Enfusion and on information currently available to their
management. Forward-looking statements include information concerning the timing of the consummation of the Mergers and the Company’s ability to satisfy the closing conditions thereof, the Company’s and Enfusion’s possible or assumed
future results of operations, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition.
Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms, but are not the
exclusive means of identifying such statements.

Forward-looking statements involve known and unknown risks, uncertainties, and other
factors, many of which are beyond the Company’s and Enfusion’s control, that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. These risks and uncertainties may cause actual results to differ materially from the Company’s and Enfusion’s current expectations and include, but are not limited to, the Company’s and Enfusion’s
ability to successfully close the Mergers, the Company’s ability to successfully integrate the operations and technology of Enfusion with those of the Company, retain and incentivize the employees of Enfusion following the close of the
acquisition, retain Enfusion’s clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the
acquisition may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under “Risk Factors” in the Company’s Annual Report on Form
10-K for the year ended December 31, 2023 filed with the SEC on February 29, 2024, and in other periodic reports filed by the Company with the SEC, which are available on the Company’s website
at https://investors.clearwateranalytics.com and on the website of the Securities and Exchange Commission at